AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04936971
Drug: Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
Trial: NCT00043706
Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
RxNorm normalized name: transforming growth factor beta 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05516472
Drug: Microbial Transplant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take microbial capsules, 2 capsules daily for 7 days
Trial: NCT05516472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo capsules
Trial: NCT05485779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral
Trial: NCT05834478
Drug: [F-18]Fallypride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
Trial: NCT06342986
Drug: CY
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
Trial: NCT06560684
Drug: TFV rectal douche
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
Trial: NCT06157255
Drug: AZD4604 Inhalation Powder, 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg dose, inhaled, fasted
Trial: NCT06157255
Drug: [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg, intravenous, fasted
Trial: NCT06157255
Drug: [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg, oral, fasted
Trial: NCT04937946
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
Trial: NCT06120491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06559618
Drug: Phage Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
Trial: NCT04263831
Drug: Interleukin-2 (aldesleukin).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Description of intervention is covered in Arm, above.
Trial: NCT03937830
Drug: Doxorubicin-Eluting Beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: used for TACE (only in patients with HCC BCLC stage B)
Trial: NCT03814109
Drug: LENINGRADO association
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated sustained-release tablet, oral, once a day.
Trial: NCT03814109
Drug: Indapamide SR 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated sustained-release tablet, oral, once a day.
Trial: NCT05939661
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
Trial: NCT05257993
Drug: JPI-547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split.
Trial: NCT05257993
Drug: modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle
Trial: NCT06247787
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive IT
Trial: NCT06247787
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive IV or PO
Trial: NCT06247787
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive IT
Trial: NCT06562608
Drug: Anticholinergic Deprescription
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
Trial: NCT06562608
Drug: No Anticholinergic Deprescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
Trial: NCT05015439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention will be supplied as a softgel capsule containing inert filler.
Trial: NCT03816488
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 1.5 g administered 2 h before surgery
Trial: NCT05231044
Drug: KX01 ointment 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.
Trial: NCT05231044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.
Trial: NCT05537948
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months.
Trial: NCT05325645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo tablets will be orally administered once weekly for 7weeks.
Trial: NCT04806503
Drug: UNR844
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution for topical ocular administration
Trial: NCT04806503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05661409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
Trial: NCT04299464
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral placebo for approximately 12 weeks.
Trial: NCT04299464
Drug: RO7017773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral RO7017773 for approximately 12 weeks.
Trial: NCT05159284
Drug: Hydrocortisone Ophthalmic
RxNorm normalized name: hydrocortisone ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
Trial: NCT06011772
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06011772
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04903223
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered to all participants on Study Day #2
Trial: NCT05702177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
Trial: NCT06564545
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Trial: NCT05268510
Drug: CapOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
Trial: NCT05764525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0 mg of VVZ-149
Trial: NCT05955924
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nicotinamide (500 mg) twice daily
Trial: NCT05955924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule twice daily
Trial: NCT05100654
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
Trial: NCT06451757
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 100 mg placebo twice daily during 52 weeks
Trial: NCT05400109
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The mechanism of action is thought to involve cross-linking of tumor cell DNA
Trial: NCT06180759
Drug: Intravenous infusion of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Placebo (saline infusion) will be administered.
Trial: NCT04990830
Drug: Inhaled Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application with Soft Mist Inhaler
Trial: NCT05919264
Drug: FOG-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
Trial: NCT05919264
Drug: mFOLFOX-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
Trial: NCT05919264
Drug: Trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
Trial: NCT04715529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
Trial: NCT05525286
Drug: SOT102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
Trial: NCT05690711
Drug: HRS8179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS8179 injection
Trial: NCT05690711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological saline
Trial: NCT04857957
Drug: Oral dose CNTX-6016 or oral dose Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTX-6016 or Placebo
Trial: NCT05378906
Drug: DRV/COBI FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of DRV/COBI FDC tablet dispersed in water as per assigned treatment sequence.
Trial: NCT05378906
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of DRV suspension as per the assigned treatment sequence.
Trial: NCT06151964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching administration volumes for SC injection
Trial: NCT00826046
Drug: Prochymal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
Trial: NCT05636176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
Trial: NCT06419361
Drug: [68Ga]Ga-Sa-DABI-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
Trial: NCT06051227
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Trial: NCT05705518
Drug: Refresh Optive Mega-3 PF
RxNorm normalized name: CARBOXYMETHYLCELLULOSE SODIUM 5 mg in 1 mL / GLYCERIN 10 mg in 1 mL / POLYSORBATE 80 5 mg in 1 mL OPHTHALMIC SOLUTION/ DROPS [Refresh Optive Mega-3 PF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
Trial: NCT05624554
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
Trial: NCT05293171
Drug: 1.25 mg/kg BL-8040 + BL-8040-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous (SC) injection
Trial: NCT05293171
Drug: 2 mg/kg BL-8040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous (SC) injection
Trial: NCT05293171
Drug: BL-8040-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SC) injection
Trial: NCT05753774
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
Trial: NCT05661903
Drug: Positron Emission Tomography / Magnetic Resonance Imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.
Trial: NCT05900388
Drug: Standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
Trial: NCT06415292
Drug: Winlevi (clascoterone) 1% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.
Trial: NCT05783479
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure
Trial: NCT06339008
Drug: LY3650150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06339008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06339008
Drug: Standard therapy for INCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as intranasal spray
Trial: NCT05741385
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine
Trial: NCT05672576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Trial: NCT04848064
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04105270
Drug: Oral Restorative Microbiota Therapy (RMT) Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly
Trial: NCT06769984
Drug: SCTT11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCTT11 dose 1, dose 2, dose 3, dose 4
Trial: NCT06769984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose 1, dose 2, dose 3, dose 4
Trial: NCT06765564
Drug: iPSC-MNP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using iPSC-MNP Cells for the Treatment of ALS Patients
Trial: NCT06263478
Drug: INCA034176
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04712435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
Trial: NCT04778397
Drug: Steroidal Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per institutional standard during consolidation.
Trial: NCT04294641
Drug: Steroid pulse (prednisone)
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.
Trial: NCT04294641
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treat or prevent bronchiolitis obliterans.
Trial: NCT05870553
Drug: Cool prep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel Preparation
Trial: NCT06007690
Drug: Bel-sar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bel-sar via suprachoroidal administration followed by laser application.
Trial: NCT05182905
Drug: AZD1390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy
Trial: NCT06298461
Drug: KleanLyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative for colonoscopy bowel preparation
Trial: NCT06717126
Drug: Investigator choice of standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator will choose the most appropriate treatment standardly given to patients
Trial: NCT06368986
Drug: VH4011499 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4011499 administered in fasted or fed conditions.
Trial: NCT06368986
Drug: VH4011499 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4011499 Dose B administered in fasted or fed conditions.